GlassScriptPhysician profile
Albert S Antonyan
NPI 1457770273
$16,914.64
in general payments reported to CMS, 2019-2025
38 companies · $3,062 in 2025
The $3,062 reported for 2025 was more than what 85% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,231 · 2020: $1,127 · 2021: $1,476 · 2022: $2,149 · 2023: $2,498 · 2024: $5,371 · 2025: $3,062.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $11K · Education: $89.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $10,840.97 |
| Education | $89.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $2,234.67 | 2019-2025 | |
| Lumenis Be INC | $2,078.05 | 2024 | Optilight |
| Abbvie INC. | $1,992.25 | 2020-2025 | Skyrizi, Rinvoq |
| Genzyme Corporation | $1,410.88 | 2019-2025 | |
| Sun Pharmaceutical Industries INC. | $1,240.56 | 2019-2025 | Ilumya |
| Janssen Biotech, INC. | $939.78 | 2019-2025 | Tremfya, Simponi, Stelara |
| Pfizer INC. | $693.01 | 2019-2023 | |
| Incyte Corporation | $613.24 | 2022-2025 | Opzelura |
| Dermavant Sciences, INC. | $581.99 | 2023-2024 | Vtama |
| E.R. Squibb & Sons, L.L.C. | $494.96 | 2022-2024 | Sotyktu |
| Organogenesis INC. | $492.63 | 2024-2025 | Via Matrix, Simplimax, Puraply Am |
| Arcutis Biotherapeutics, INC. | $473.47 | 2023-2025 | Zoryve |
| Regeneron Healthcare Solutions, INC. | $461.21 | 2019-2024 | Dupixent |
| Galderma Laboratories, L.P. | $455.98 | 2019-2025 | Aklief, Nemluvio |
| Ucb, INC. | $420.38 | 2019-2025 | Bimzelx |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $372.49 | 2019-2024 | Otezla |
| Lilly USA, LLC | $337.01 | 2019-2025 | Taltz, Ebglyss, Olumiant |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $335.64 | 2019-2025 | Siliq, Targretin, Arazlo |
| Almirall LLC | $299.29 | 2023-2025 | Seysara, Klisyri |
| Organon LLC | $237.10 | 2025 | Vtama |
| Leo Pharma INC. | $149.16 | 2019-2025 | Adbry, Anzupgo |
| Helsinn Therapeutics (U.S.), INC. | $99.31 | 2019-2023 | Valchlor |
| Journey Medical Corporation | $85.41 | 2021-2022 | |
| Celgene Corporation | $72.86 | 2019 | |
| Vyne Pharmaceuticals INC. | $64.73 | 2020-2021 | |
| Biofrontera INC. | $42.77 | 2023-2024 | Xepi, Bf-Rhodoled, Ameluz |
| Strata Skin Sciences, INC. | $35.29 | 2025 | Xtrac |
| Mayne Pharma Commercial LLC | $28.32 | 2024-2025 | |
| Krystal Biotech INC | $23.84 | 2023 | Vyjuvek |
| Verrica Pharmaceuticals INC. | $21.19 | 2025 | Ycanth |
| Fresenius Kabi USA, LLC | $19.68 | 2023 | |
| Revance Therapeutics, INC. | $19.09 | 2024 | Daxxify |
| Botanix Sb INC | $17.96 | 2025 | Sofdra |
| Dusa Pharmaceuticals, INC. | $16.15 | 2019 | |
| Phadia US INC. | $14.38 | 2020 | |
| Epi Health, LLC | $13.93 | 2022 | |
| Mylan Pharmaceuticals INC. | $13.19 | 2019 | |
| Prugen, INC. Pharmaceuticals | $12.79 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Albert Antonyan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.